NCT06538623View on ClinicalTrials.gov

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pancreatic NeoplasmsNeoplasm MetastasisHepatic Metastasis of Pancreatic Cancer
Interventions
DRUG

Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin

Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);

DRUG

Tegodor

Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.

Trial Locations (1)

2000010

RECRUITING

Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER